Novartis AG
NOVNN MM
NOVNN MMNovartis AG
Mexico CompositeCompany Description
- Full Time Employees
- 76,057
- Sector
- Healthcare
- Industry
- Drug Manufacturers—General
- Address
- Lichtstrasse 35 Basel Switzerland 4056
- IPO Date
- Apr 3, 1995
- Website
- www.novartis.com
- Business
- Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company News
Morphosys says Novartis takeover progressing as planned for H1 2024
Sanofi Posts Strong Sales Growth With New Hemophilia Medicine
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Roche Sales Decline in Last Quarter of Pandemic Impact
Novartis accused of promoting asthma drug for preterm labor despite brain risk
POINT MARCHÉS L'Europe finit dans le vert avec de solides résultats de sociétés
POINT MARCHÉS Les résultats d'entreprises soutiennent les actions
Five Things You Need to Know to Start Your Day: Americas
AMERICAS Tanking Tesla reports, Europe business beats
BOURSE L'Europe progresse avant les PMI, animée par les résultats
Techs boost STOXX to one-week high; euro zone data on tap
Novartis revoit à la hausse ses prévisions pour 2024
Novartis Raises Forecast as Sales of New Blockbusters Climb
POINT MARCHÉS L'Europe attendue en hausse prudente avant les PMI
Novartis lifts FY guidance after Q1 results beat expectations
Five Things You Need to Know to Start Your Day: Europe
Novartis (NVS) to Report Q1 Earnings: What to Expect?
US FDA mandates label updates on CAR-T cancer therapies
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Weight-loss drug developer Metsera raises $290 million in funding